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Nuclear import/exportZIC3, an X-linked zinc ﬁnger transcription factor, was the ﬁrst identiﬁed gene involved in establishing normal
left–right patterning in humans. Mutations in the Zic3 gene in patients cause heterotaxy, which includes
congenital heart defects. However, very little is known about how the function of the ZIC3 protein is regulated.
Sumoylation is a posttranslational modiﬁcation process in which a group of small ubiquitin-like modiﬁer
(SUMO) proteins is covalently attached to targets via a series of enzymatic reactions. Here, we report for the
ﬁrst time that sumoylation targets human ZIC3 primarily on the consensus lysine residue K248, which is critical
for the nuclear retention of ZIC3. Consequently, SUMOmodiﬁcation potentiates the repressive activity of ZIC3 on
the promoter of its target gene cardiac α-actin, and the mutation of lysine 248 to arginine (K248R) abolishes its
repressive function. We further revealed that ZIC3 variants with mutations found in human patients with
congenital anomalies exhibit aberrant sumoylation activity, which at least partially accounts for their
cytoplasmic diffusion. Improved sumoylation of human disease-associated ZIC3 variants reestablishes
their nuclear occupancy in the presence of SUMO E3 ligase and SUMO-1. Thus, the altered sumoylation
status of ZIC3 underpins the developmental abnormalities associated with these ZIC3 mutants. The SUMO
targeting consensus sequence in ZIC3 is highly conserved in its paralogs and orthologs, pointing to
sumoylation as a general mechanism underlying the functional control of ZIC proteins. This study provides
a potential therapeutic strategy to regain the normal subcellular distribution and function of ZIC3 mutants
by restoring SUMO conjugation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
ZIC (zincﬁnger in the cerebellum) genes belong to theGli superfamily
of transcription factors. The ZIC gene family is composed of ﬁvemembers
(ZIC1, ZIC2, ZIC3, ZIC4, and ZIC5) in human andmouse, all of which share
highly conserved ﬁve tandemC2H2 zinc ﬁnger (ZF)motifs [1]. Mutations
in ZIC genes causally underlie a variety of congenital malformations such
as holoprosencephaly and neural tube defects in murine models and in
humans [2–7], indicating the essentiality of ZIC proteins to proper organ-
ogenesis. Of these ﬁve family members, ZIC3 is the only X-linked gene
and mutations of ZIC3 are associated with human laterality defects and
sporadic congenital cardiac structural malformations [8]. The exact
mechanisms underlying the various disease manifestations associated
with ZIC3 mutations are not well understood; however, the role of ZIC3
in deﬁning left–right asymmetry during vertebrate embryogenesis waster for Stem Cell Engineering,
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ights reserved.at least partially attributable to its regulation of nodal expression in the
node [9]. The incomplete phenotypic penetrance of ZIC3 mutations in
humans may also be inﬂuenced by gene modiﬁer(s) and environmental
cues [10,11].
One important feature that governs ZIC3 function is
nucleocytoplasmic trafﬁcking. The mechanisms underlying its
subcellular shuttling were previously studied and the existence of
nuclear localization signals (NLS) and a nuclear export signal (NES)
has been proposed as a mechanism whereby proper nuclear occupancy
and function of ZIC3 was maintained [12,13]. Interestingly, a number of
human disease-linked naturally occurring missense mutations in ZIC3
such as C253S (conversion of cysteine 253 to serine),W255G (conversion
of tryptophan 255 to glycine), H286R (conversion of histidine 286
to arginine), T323M (conversion of threonine 323 to methionine)
resulted in cytoplasmic retention and diminished function [14,15].
However, some of these mutations (i.e., C253S, W255G, and
H286R) are not localized in any known NES or NLS. Moreover, the
W255G mutation did not appear to signiﬁcantly alter the structure
of ZIC3 [13]. Thus, whether there are any unifying mechanisms that
are associated with the extranuclear diffusion of these mutants
remain to be elucidated.
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tions modulate functions of a variety of proteins involved in a wide
spectrum of cellular events. To this end, whether and how the func-
tion of ZIC proteins is regulated by posttranslational modiﬁca-
tion(s) has not been well studied. The only clue so far is a study
demonstrating that the phosphorylation of ZIC2 by DNA-PK
promoted its function via enhanced stability of the protein complex
containing ZIC2 and RNA helicase A, and that, conversely, de-
phosphorylation inhibited ZIC2's activity [16].
Sumoylation is a posttranslational modiﬁcation in which SUMO
(small ubiquitin-related modiﬁer) proteins are covalently and
reversibly conjugated to the speciﬁc lysine residue(s) via a series
of enzymatic reactions involving the heteromeric activating
enzyme E1 (SAE1/2), the conjugation enzyme E2 (Ubc9), and a
number of SUMO E3 ligases represented by PIAS family; subse-
quently, the activity of these targets are altered via multiple mech-
anisms, including changes in subcellular localization and/or protein
stability [17]. The SUMO-targeting consensus sequence has been
identiﬁed as ΨKXE (where Ψ represents a bulky hydrophobic
amino acid, and X represents any residue) [18]; however, SUMO
conjugation can also occur on non-canonical lysine residues,
particularly in the presence of SUMO E3 ligases. SUMOmodiﬁcation
has been implicated in the pathogenesis of a number of human
diseases [19–22]. Our group and others have identiﬁed a multitude
of SUMO targets such as GATA4, myocardin, Nkx2.5, Prox1 [23–28]
that are critical for cardiovascular development and function, and
have demonstrated that decreased SUMO-1 conjugation in murine
hearts, induced either by SUMO-1 knockout or by cardiac
overexpression of SENP2 (a SUMO isopeptidase), caused congenital
heart defects and/or cardiac dysfunction [29,30]. These studies
substantiate the essential role of SUMO conjugation pathway in
proper cardiac morphogenesis and function (see reviews [31,32]).
Here we report for the ﬁrst time that SUMO regulates nucleocytoplasmic
shuttling and the function of ZIC3. A number of humandisease-associated
ZIC3 mutants that affect subcellular trafﬁcking also exhibit aberrant
sumoylation; restoring the sumoylation of these mutants reestablish
their nuclear occupancy. Thus, sumoylation may serve as a general
mechanism governing the nucleocytoplasmic shuttling of ZIC3, and
the altered sumoylation status of ZIC3 mutants may be potentially
associated with disease manifestations. Also, since the SUMO target
sequence in the ZIC3 protein is highly conserved among its paralogs
and orthologs, this posttranslational modiﬁcation may represent a
general mechanism controlling the function of ZIC proteins.2. Materials and methods
2.1. Plasmid constructions
Vectors expressing HA-tagged human ZIC3 WT and its human
disease-associated mutants C253S, H285R, T323M, K405E, P217A
were generous gifts from Dr. John Belmont (Baylor College of
Medicine, Houston, Texas) [33]. The cDNAs of ZIC3 WT and its
mutants were then PCR-ampliﬁed and subcloned into pcDNA-4A-
V5/His expression vector (Invitrogen). SUMO-1-fused human ZIC3
expression vectorwas generated by PCR using corresponding oligonucle-
otides covering SUMO-1 cDNA, which were thereafter subcloned into
pcDNA4A-ZIC3-V5/His vector with KpnI and BamHI at the 5′ end of ZIC3
cDNA. ZIC3 consensus SUMO site mutant K248R (ZIC3-K248R) was
generated by a two-step PCR protocol. Human ZIC3W255Gmutant was
generated using site-directed mutagenesis kit (Stratagene). All mutants
were conﬁrmed by sequencing. The cardiac alpha actin promoter-driven
luciferase reporter construct (Ca-actin-Luc) was previously described
[34]. SUMO-1, SUMO-2, SUMO-3 expression vectors, PIAS1, PIAS3,
PIASy, PIASxα, PIASxβ, and PIAS1-RING domain mutant (PIAS1-RING
mut) were detailed previously [25,35].2.2. Antibodies
Anti-V5-HRP antibody (Invitrogen, R961-25), anti-HA-HRP anti-
body (Genscript, A00169), anti-GAPDH-HRP antibody (Santa Cruz,
sc-20357), and anti-SUMO-1 antibody (Santa Cruz, sc-9060).2.3. Cell culture, transient transfection
The regular Hela cells and the stable Hela cell line that expresses
6xHis-tagged SUMO-1 (su-Hela), which was generously provided
by Dr. Alfred Vertegaal (Leiden University Medical Center, Leiden,
Netherlands) [36], were used in the present study. Reporter
transactivation assays were performed in 12-well plates, whereas tran-
sient transfections for Western blotting were carried out in 10 cm
plates. At least two independent reporter assays were performed to ob-
tain conclusive data. Hela cells were harvested 48 h post-transfection,
and then luciferase activity assays were executed with Monolight
™3010 (AmershamBiosciences). ForWestern blotting assays, expression
vectors (0.5 μg each) as indicated in each ﬁgure legend were transfected
into Hela cells. Cell lysates were puriﬁed after 48 hours transfection and
subjected to 4–12% Bis-Tris NuPage gel, transferred to polyvinylidene
diﬂuoride (PVDF) membrane, visualized by desired antibody using ECL
plus (GE Healthcare) or Immobolin Western (Millipore).2.4. Immunocytoﬂuorescence
The immunoﬂuorescence staining was detailed previously [37].
Brieﬂy, to examine the subcellular localization of human ZIC3 WT and
its mutants, V5-tagged ZIC3 WT or its mutants were transfected into
Hela cells in the absence or presence of the nuclear export inhibitor
Leptomycin B (LMB) (50 ng/μl) for 12 h. Transfected cells were ﬁxed
and blocked. Then sections were incubated with the primary mouse
anti-V5 antibody and washed, followed by Alexa ﬂuor® 488 donkey
anti-mouse secondary antibody (Invitrogen, A21202). To examine the
effects of SUMO conjugation on subcellular localization of human ZIC3
mutants, each V5-tagged ZIC3 mutant of interest was transfected into
su-Hela alone, or together with HA-epitoped PIAS1 WT or PIAS1-Ring
mutant (PIAS1-M), followed by double immunoﬂuorescence staining
against HA and V5 epitopes. All slides weremounted and photographed
under a Leica ﬂuorescent microscope. The number of exclusively
nuclear stained cells was scored against the number of both cytoplasmic
and nuclear stained cells (diffused staining) from 100 randomly select-
ed cells per group, and was summarized from two independent assays
for each staining.2.5. In vivo sumoylation and Ni2+-NTA chromatography
Ni-NTA chromatography, which was described previously [24,25],
was used to evaluate the SUMO conjugation of human ZIC3 WT and
its mutants in vivo. ZIC3-WT, or one of its human disease-associated
mutants K248R, C253S, W255G, H285R, T323M, K405E or P217A, was
transfected into Hela cells in the absence or presence of ﬂag-tagged
SUMO-1 as indicated in each ﬁgure legend. To determine whether
PIAS1 potentiates the sumoylation of ZIC3 in vivo, the similar transfec-
tion assays were also performed in the presence of the encoding vector
for either PIAS1 WT or its RING-mut.2.6. Statistical analysis
DATA are presented as the mean ± SEM. The unpaired Student's t
test is applied to determine statistical signiﬁcance between groups
when applicable and shown in each ﬁgure legend. The p value less
than 0.05 is considered as signiﬁcant.
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3.1. ZIC3 is a novel SUMO substrate
Fig. 1A upper panel shows the representative structure of human
ZIC3, including ﬁve zinc ﬁnger (ZF) domains, and the relative locations
of NES (nuclear export signal) and NLS (nuclear localization signal)
[12]. It also shows the location of each of six human disease-linked
ZIC3 mutants that are selected for the assays in the present study. To
identify if ZIC3 is a potential SUMO target, we ﬁrst used bioinformatics
program SUMOsp and revealed one putative sumoylation motif with a
high score (3.389) in human ZIC3, IK248VE, which conforms to the
SUMO targeting consensus sequence previously identiﬁed [18]. This
IKVEmotif is well conserved in all of its paralogs as well as its orthologs
examined, including human,mouse,Xenopus, rat and zebra ﬁsh (Fig. 1A,
lower panel, boxed gray region), indicative of its potential importance
for functional regulation. To determine whether SUMO targets ZIC3
and whether the K248 is a SUMO site, Ni-NTA pulldown assay was
conducted on Hela cell lysates transfected with V5-6xHis-tagged ZIC3
WT or its mutant K248R (conversion of lysine 248 to arginine), in the
presence or absence of SUMO-1 and/or PIAS1, the latter which is a
potent sumoylation E3 ligase. A retarded band which is equivalent to
the addition of one SUMO molecule and is responsive to anti-V5 anti-
body is only observed in the presence of both ZIC3 WT and SUMO-1,
but not ZIC3 alone (SF1, compare lane 1 with lane 2), suggesting ZIC3Fig. 1.ZIC3 is a target of post-translational sumoylation. (A)A schematic representation of them
249–415 aa), relative locations of NES (nuclear export signal) and NLS (nuclear localization si
assays in the present study. The lower panel shows lysine 248 (K, arrow), the primary SUMO site
Alignment Tool (COBALT) is used for sequence alignment. h: human;m:mouse; x:Xenopus; r: ra
(B)Western blotting using either anti-V5-HRP antibodyor anti-SUMO-1 antibody conﬁrms that
in ZIC3WT (lane 2). Ni-NTApulldown assayswere performedonHela cell lysates expressingV5
The blot was ﬁrst probed with anti-V5 antibody (upper panel), and then was stripped and repro
Arrows indicate non-speciﬁc bands which are not reactive with anti-SUMO-1 antibody. (C) Ni-N
ZIC3 WT/SUMO-1, or in the presence of either PIAS1 WT or PIAS1 RING-mut. PIAS1 WT, but n
lane 3). Blot: anti-V5. (D) The repressive activity of ZIC3 on cardiacα actin promoter is enhanced
(K248R). Promoter activity is expressed as the ratio of luciferase activity induced by the presence o
activity in the control group is taken as 1.as a SUMO substrate. This slow migratory band is hardly seen by anti-
V5 antibody in the lane containing the mutant K248R and SUMO-1
(SF1, compare lane 5 with lane 2), while free K248Rmutant was equiv-
alently precipitated by Ni-NTA beads as ZIC3 WT, indicating that K248
was the principal SUMO site in ZIC3. While PIAS1 enhances the SUMO
conjugation to ZIC3 WT by introducing additional more slow migrating
bands that are detected by anti-V5 antibody as expected (SF1, compare
lane 3 with lane 2), it also induces sumoylation of the K248Rmutant in
the presence of ectopically expressed SUMO-1 (SF1, lane 6). However,
the PIAS1-induced sumoylation pattern and intensity of K248Rmutant
is different from that of ZIC3 WT: the sumoylated bands of K248R
mutant migrate faster in the western gel, and are weaker compared
with their counterparts in ZIC3 WT (SF1, compare lane 6 with lane 3),
suggesting an activation of non-canonical SUMO site(s) by PIAS1. To
further conﬁrm that the slow migratory band is SUMO modiﬁed ZIC3,
we used the similar experimental strategy and found that the slower
migratory band observed in SF1 lane 2 is reproduced and responsive
to both antibodies against V5 and SUMO-1 (Fig. 1B, lane 2, asterisks),
corroborating ZIC3 as a novel SUMO substrate. In line with the
observation shown in SF1, SUMO conjugated K248R is much weaker,
and migrates faster than that of ZIC3 WT (Fig. 1B, lane 4, asterisks).
Thus, conversion of lysine 248 to arginine appears to activate a weak
non-classical SUMO acceptor site, which otherwise would be latent in
the presence of the intact SUMO targeting sequence. Additionally, the
mutation on another SUMO consensus sequence with a low scoreajor structures inhuman ZIC3. The upper panel shows theﬁve zincﬁnger domains (#1–#5,
gnal), and the relative position of each of six human-linked ZIC3 variants selected for the
,which is highly conserved among ZIC3 orthologs and paralogs. Constraint-basedMultiple
t; z: zebraﬁsh. (B–C) Identiﬁcation of lysine 248 as theprimary SUMOacceptor site in ZIC3.
the SUMOmodiﬁcation of ZIC3-K248Rmutant (lane 4) is greatly reduced compared to that
-6xHis-tagged ZIC3WT or K248Rmutant in thepresence or absence of exogenous SUMO-1.
bedwith anti-SUMO-1 antibody (lower panel). Asterisks indicate SUMO-conjugated ZIC3.
TA was performed on cell lysates puriﬁed from Hela cells transfected with V5-6xHis-tagged
ot PIAS1 RING-mut, enhances the SUMO modiﬁcation of ZIC3-WT (compare lane 2 with
by SUMO-1 fusion (SUMO-1-ZIC3), but is abolished by themutation of lysine 248 to arginine
f speciﬁc factor(s) to the control groupwith the presence of empty vector only. The luciferase
Fig. 2. SUMO site K248 is required for nuclear localization of ZIC3. (A–B) SUMO site mutation leads to diffused subcellular localization of ZIC3. (A) Immunocytoﬂuorescence staining was
performed on Hela cells transfected with HA-tagged ZIC3WT (a–a″), or K248R mutant (b–c″) using antibody against HA. While HA-ZIC3WT is exclusively located in the nucleus (a–a″),
while the HA-K248Rmutant exhibits diffused subcellular localization (in both nucleus and cytoplasm) (b–b″). The presence of nuclear export inhibitor Leptomycin B (LMB) reestablishes
the nuclear occupancy of K248R (c–c″). Green: ZIC3WT in a–a″, ZIC3 K248R in b–c″; blue: DAPI. Ampliﬁcation, 40×. The score of the number of cells showing exclusively nuclear staining
vs. that showing diffused staining in each group is shown in B. The scores were obtained from randomly selected 100 cells/group, and were summarized from two independent assays.
Black column, exclusively nuclear; shaded column, diffused. (C–D) PIAS1 WT/SUMO-1 restores the nuclear localization of K248R mutant. Double immunocytoﬂuorescence staining was
performed on SUMO-1-stably expressed Hela cells (su-Hela) transfected with V5-tagged ZIC3 alone (a–a‴), or in the presence of HA-epitoped PIAS1 WT (b–b‴) or PIAS1 RING-mut
(PIASA1-M, c–c‴). Note that PIAS1 restores the nuclear localization of K248R (b–b‴), while PIAS1 Ring domain mutant (PIAS1-M) does not (c–c‴). Green: V5-ZIC3-K248R; red: HA-PIAS1
WT-HA in b–b‴, HA-PIAS1 Ring domain mutant in c–c‴, blue: DAPI. The scores were obtained from randomly selected 100 cells/group, and were summarized from two independent assays.
Black column, exclusively nuclear; white column, diffused. Ampliﬁcation, 40×. Scale bar: 100 μm.
2728 L. Chen et al. / Biochimica et Biophysica Acta 1833 (2013) 2725–2733(0.422), FK359CE, does not show any signiﬁcant effect on ZIC3
sumoylation (data not shown). While PIAS1 WT stimulates
sumoylation of ZIC3, its RING-mut does not (Fig. 1C). Collectively,
these ﬁndings indicate that lysine 248 in ZIC3 is the primary
SUMO site, and that PIAS1 substantiates SUMO attachment to ZIC3
via its RING domain.
Next, to assess the functional consequence of SUMO conjugation to
ZIC3, luciferase activity assay was performed on Hela cells transfected
with Ca-actin-Luc in the presence of ZIC3 WT, SUMO-1-fused ZIC3
WT (SUMO-1-ZIC3), or the mutant K248R, respectively. Consistent
with the previous report [33], ZIC3 WT suppresses the activity of
Ca-actin-Luc. While SUMO-1-ZIC3 shows more repressive effects
on this promoter compared with ZIC3 WT, the mutation of lysine
248 to arginine abolishes it (Fig. 1D). Taken together, these data
suggest that the SUMO conjugation potentiates the repressive func-
tion of ZIC3.
3.2. Speciﬁcity of the SUMO conjugation machinery in ZIC3 sumoylation
SUMO family consists of three conjugatable members, SUMO-1,
SUMO-2 and SUMO-3, which possess substrate speciﬁcity. To exploreif differential modiﬁcation of ZIC3 by SUMO-1, -2 and -3 exists, Ni-NTA
pulldown assays were performed on Hela cell lysates containing
V5-6xHis-tagged ZIC3 WT in the presence of encoding vectors for
SUMO-1, SUMO-2 or SUMO-3, respectively. As shown in SF2.A, ZIC3
is modiﬁed by all these three SUMO proteins at equivalent levels.
There are mainly ﬁve members in the SUMO E3 ligase PIAS family
(PIAS1, PIAS3, PIASy, PIASxα and xβ). To investigate if PIAS proteins
differentially regulate SUMO-1 modiﬁcation of ZIC3, the combina-
tion of V5-6xHis-tagged ZIC3 WT and SUMO-1 was co-transfected
into Hela cells together with one of those PIAS proteins, followed
by above-mentionedNi-NTApulldownassays. In the absence of PIAS pro-
tein, the combination of ZIC3/SUMO-1 displays one clear slow migrating
band as expected (SF2.B, lane 2), and all PIAS proteins are able to promote
the appearance of at least one additional retarded migratory band, with
PIAS1 as the strongest enhancer of SUMO-1 conjugation of ZIC3 (SF2.B,
compare lane 3 with lane 4–7). However, only PIAS1, 3 and y, but not
PIASxα andxβ, enhance the sumoylation of ZIC3 by SUMO-3 by introduc-
ing at least one additional retarded migratory band (SF2.C). Therefore,
while SUMO isoforms exhibits equivalent capacity to modify ZIC3, PIAS
E3 ligases display differential discrimination for SUMO proteins to be
covalently attached to ZIC3.
Fig. 3. Human ZIC3 variants displayed deﬁcient SUMO conjugation. Ni-NTA pulldown
assays were performed on Hela cell lysates containing V5-6xHis-tagged ZIC3 WT or one
of its mutants in the absence or presence of ectopically expressed SUMO-1 as indicated.
Upper panel, three mutants (C253S, W255G, H286R) show decreased SUMO conjugation
compared with ZIC3 WT; lower panel, one mutant (T323M) shows decreased SUMO
conjugation compared with ZIC3 WT. Asterisks indicate SUMO-conjugated ZIC3. Blot,
anti-V5.
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Nuclear localization of ZIC3 plays an important role in regulating
its function [12,13]. Since sumoylation may regulate the activity of
its substrates via altering its subcellular distribution, we asked if
K248 contributed to maintain ZIC3's nuclear localization. Immuno-
staining against HA tag was performed on Hela cells transfected
with HA-epitoped ZIC3 WT or K248R mutant, respectively. Consis-
tent with previous reports, ZIC3WT is predominantly localizedwith-
in the nucleus (nearly 100%) (Fig. 2A, a–a″, and B), however, ~90% of
K248R exhibits both nuclear and cytoplasmic localizations (Fig. 2A,
b–b″, and B), indicating that K248 is critically involved in ZIC3's
nucleocytoplasmic shuttling. Next, to probe if nuclear export is in-
volved in K248R cytoplasmic diffusion, leptomycin B (LMB), a
repressor of nuclear export, was applied to the Hela cells expressing
HA-tagged K248R. The presence of LMB results in the nuclear
retention of K248R up to ~90% (Fig. 2A, c–c″, and B). Collectively,
these ﬁndings prove that the lysine 248 is implicated in mediating
the subcellular localization of ZIC3.
Since lysine 248 is the primary SUMO acceptor site, we next asked if
SUMO conjugation is directly involved in regulating the nuclear occupan-
cy of ZIC3. Since PIAS1 WT but not PIAS1 RING-mut promotes the
sumoylation of K248R in the presence of overexpressed SUMO-1
(Fig. 1C), we used this system to test whether the diffused subcellular lo-
calization of K248R is affected by PIAS1 WT/SUMO-1. V5-6xHis-tagged
K248R mutant was transfected into su-Hela cells stably expressing
SUMO-1 alone, or together with HA-tagged PIAS1 WT or RING-mut, re-
spectively. As expected, K248R mutant shows extranuclear distribution
(Fig. 2C, a–a″). The addition of PIAS1WT results in ~90% nuclear accumu-
lation of K248R (Fig. 2C, b–b″ and D), whereas PIAS1 RING-mut does not
signiﬁcantly alter the diffused subcellular localization of K248R (~10%)
(Fig. 2C, c–c″ and D). In accordance with a previous report [38], both
PIAS1WT and RING-mut exhibit no signiﬁcant difference in their subcel-
lular localization patterns (data not shown), and RING-mut is physically
associated with ZIC3 as well as PIAS1WT (data not shown), demonstrat-
ing that PIAS1 does not sequester ZIC3within the nucleus via physical as-
sociation. We therefore conclude that sumoylation contributes to retain
the nuclear localization of ZIC3 K248R mutant.
3.4. Defective SUMO conjugation involved in aberrant subcellular
distribution of human ZIC3 mutants
A number of disease-associated human ZIC3 mutants exhibited im-
pairednuclear localization [15]. To interrogate if thosenaturally occurring
mutations affect ZIC3 sumoylation, six ZIC3 variantswith various localiza-
tions ofmutated sites (Fig. 1A), three in ZF1 (C253S,W255G,H286R), one
in ZF2 (T323M), one in ZF5 (K408E), and one in the N-terminal domain
(P217A), were tested for SUMO modiﬁcation. Ni-NTA pulldown was
performed on the Hela cells transfected with V5-6xHis-tagged ZIC3 WT
or one of those mutants in the absence or presence of SUMO-1. While
free ZIC3WT andmutants are precipitated at comparable levels, the mu-
tants C253S, W255G, H286R, and T323M display substantially decreased
sumoylation (Fig. 3, asterisks). The other twomutants, P217A and K405E,
show no signiﬁcant alteration of SUMO modiﬁcation (Fig. 3, asterisks).
The above observations coincide respectively with the diffused subcellu-
lar localization of C253S,W255G, H286R, and T323M, andwith relatively
normal subcellular distribution of P217A and K408E [15]. We then hy-
pothesized that an improvement of sumoylation of these mutants
would improve their nuclear occupancy. Three mutants C253S, W255G
and H286R are selected to test this hypothesis. First, we investigated if
PIAS1WT was able to potentiate the sumoylation of these ZIC3 mutants.
Ni-NTA pulldown assays were performed on 6xHis-SUMO-1 stably
expressed Hela cells containing one of the V5-6xHis-tagged three
mutants alone, or together with PIAS1 WT or RING-mut, respectively.
As expected, PIAS WT, but not RING-mut, substantially improves
sumoylation of these three mutants (Fig. 4A). Next, each of theseV5-tagged mutants was transfected with either HA-tagged PIAS1
WT or RING-mut into the su-Hela cells stably expressing SUMO-1,
followed by double immunostaining against V5 and HA. All these
three mutants show signiﬁcantly improved nuclear accumulation
in the presence of HA-PIAS1 WT, but not with HA-PIAS1-RING-mut
(Fig. 4B, b–g″, see double HA+/V5+ cells, and 6D–F). As a control,
P217A, which exhibits no signiﬁcantly altered subcellular distribution
and sumoylation, mainly stays in the nucleus in the presence of
PIAS1-M (Fig. 4B, a–a″ and C), in agreement with the previous report
[15]. Taken together, these ﬁndings demonstrate that sumoylation
is negatively affected in a number of naturally occurring disease-
associated ZIC3 variants that also exhibit aberrant subcellular distribu-
tion, and that improved sumoylation of these mutants restores their
nuclear accumulation.
3.5. LMB promotes nuclear accumulation of human ZIC3 variants with
impaired SUMO conjugation
Since SUMO conjugation is involved in nucleocytoplasmic trafﬁcking
of ZIC3, and LMB promotes nuclear accumulation of sumoylation-
deﬁcient ZIC3mutant K248R,we asked if LMB could also improve nuclear
localization of those human mutants that exhibit abnormal subcellular
trafﬁcking. Immunostaining was performed on Hela cells transfected
with one of the expression vectors encoding V5-tagged P217A
(SUMOylation-normal mutant as a control), C253S or W255G alone or
together with LMB. In line with the previous reports, P217A primarily
stays in the nucleus, and the sumoylation-deﬁcient mutants C253S and
W255G exhibit diffused distribution (Fig. 5A, a–c). While LMB has little
effects on the subcellular localization of P217A (Fig. 5A, a′, B), it substan-
tially improves nuclear localization of C253S and W255G (Fig. 5A, b′–c′,
and C-D, from ~10% to ~95% for C253S and from ~18% to ~95% for
W255G). LMB also efﬁciently diminishes the extranuclear diffusion of
H286R (data not shown). Thus, these observations argue that the similar
molecular phenotype(s) underpin the abnormal subcellular localization
of sumoylation-deﬁcient naturally occurring ZIC3 variants and the
SUMO site mutant K248R.
4. Discussion
In the present study, we report for the ﬁrst time that ZIC3 is a SUMO
substrate. We ﬁrst reveal that lysine residue 248, which is localized
immediately upstream of ZF1 of ZIC3, is the principal SUMO acceptor
Fig. 4. Improved sumoylation of human ZIC3 variants restores their nuclear occupancy. (A) SUMOE3-ligase PIAS1WT, but not the RING-mut, enhances the sumoylation of humanmutants
C253S,W255G andH286R. Ni-NTA pulldown assayswere performed in su-Hela cell lysates containing V5-6xHis-tagged ZIC3mutant alone, or in the presence of either HA-epitoped PIAS1
WT or RING-mut (RING-M). Blot, anti-V5. (B) The presence of PIAS1WT, but not PIAS1-RING-mut, restores the nuclear occupancy of sumoylation-deﬁcient ZIC3 variants in su-Hela cells.
Double immunocytoﬂuorescence staining using antibodies against V5 (green) and HA (red)was performed on su-Hela cells transfectedwith one of V5-tagged ZIC3 variants together with
either HA-epitoped PIAS1 WT or RING-mut (RING-M). Note that the sumoylation-deﬁcient human ZIC3 mutants C253S, W255G and H286R display substantially improves nuclear
accumulation in the presence of PIAS1 WT compared with that in the presence of PIAS1-M. C253S, compare b–b″ with c–c″; W255G, compare d–d″ with e–e′; H286R, compare f–f″
with g–g″. The sumoylation-normal human ZIC3mutant P217A, which exhibits primarily nuclear localization, serves as a control in the presence of HA-epitoped PIAS1-M (a–a″). Arrows
indicate diffused staining. Green: V5-tagged human ZIC3mutants-V5; red: HA-tagged PIAS1WT or Ring-M. Blue: DAPI staining. Themiddle and right panels of B (40×magniﬁcation) are
the ampliﬁcation of the boxed areas in the right panels of B (20× magniﬁcation). Scale bar: 100 μm. (C–F) The scores were obtained from randomly selected 100 cells/group, and were
summarized from two independent assays. Black column, exclusively nuclear; white column, diffused localization.
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SUMO domain in ZIC3. We further examine the effects of SUMO con-
jugation on ZIC3 activity using two variants, SUMO-1 fused ZIC3
(SUMO-1-ZIC3) and a SUMO site mutant of ZIC3 (K248R), in the
well-established model system in which ZIC3 represses the activity of
Ca-actin-Luc reporter [33]. SUMO-1-ZIC3 displays a more inhibitory
effect than ZIC3WT, while themutation of lysine 248 to arginine totally
abolishes its repressive effect. Although SUMO-1-ligated ZIC3 is not
identical to the natively SUMO-conjugated form, this type of variant
has often been employed to test the activity of SUMO-conjugated tar-
gets in vivo in the SUMO ﬁeld [39–42]. The precise molecular basis
underlying the inhibitory effects of ZIC3 on cardiac α-actin promoter
remains unclear, as are the mechanisms bywhich Ca-actin-Luc exhibits
higher activity in the presence of K248R thanWTZIC3. It is possible that
ZIC3 recruits some corepressor(s) to execute this repressive function.
Alternatively, ZIC3 may inhibit this cardiac promoter by competing
with some (as yet unknown) activator(s) for binding to this promoter.
Thus, the removal of the suppressive impact of ZIC3 on Ca-actin-Luc
by the mutation of K248R could be at least partially attributed to itscytoplasmic relocalization (see below). The effect of this relocalization
may be to either “piggyback” the corepressor(s) to cytoplasm and/or
to increase the binding of activator(s) to this promoter, leading to the
activation of this cardiac promoter. Whether these hypotheses hold
true requires further investigation. Given that SUMO-1-Zic3 represses
Ca-actin-Luc more than ZIC3 WT, we conclude that SUMO attachment
is associated with ZIC3's repressive activity.
SUMO conjugation was involved in regulating the subnuclear or
subcellular trafﬁcking of a number of target proteins [41,43,44]. Previous
studies deﬁned NLS and NES between ZF2 and ZF5 in ZIC3 [12,13],
and these signals were suggested to cooperatively modulate ZIC3's
nucleocytoplasmic trafﬁcking. The major SUMO site lysine 248, despite
being distant from the NLS and NES, is critically involved in regulating
the nucleocytoplasmic shuttling of ZIC3, and the extranuclear relocation
caused by this site mutation is blocked by LMB. For any given mutated
nuclear protein, the abnormal cytoplasmic distributionmay be explained
basically by the following: 1) the protein is less efﬁciently imported into
the nucleus but still exported at the same rate, or 2) the nuclear import
rate is unchanged but export rate is enhanced. In either of these two
Fig. 5. LMB improves nuclear localization of sumoylation-deﬁcient human ZIC3 Mutants. (A) Immunocytoﬂuorescence staining using antibody against V5 was performed on Hela cells
transfected with V5-tagged ZIC3 mutants in the absence or presence of LMB as indicated. The sumoylation-normal human ZIC3 mutant P217A displays primarily nuclear localization
(a), while C253S and W255G mutants are diffused in both nucleus and cytoplasm (b & c). LMB has no effects on the nuclear localization of P217A (a′), but greatly restores the nuclear
accumulation of C253S andW255G (b′ & c′). Green: V5-tagged ZIC3mutant; blue: DAPI. (B–D) The scores were obtained from randomly selected 100 cells/group, and were summarized
from two independent assays. Black column, exclusively nuclear; white column, diffused localization. Ampliﬁcation, 40×. Scale bar: 100 μm.
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would lead to the nuclear accumulation of the mutant protein. To this
end, we currently do not have evidence for either scenario for the
K248R mutant. However, given that sumoylation was shown to be asso-
ciated with nuclear import [45], it is likely that the mutation of K248
impacts the function of NLS. Another interesting but unaddressed issue
is whether SUMO modiﬁcation leads to ZIC3's nuclear localization or
whether nuclear localization of ZIC3 leads to its sumoylation.
Unexpectedly, K248R mutation introduces a secondary weak
sumoylation site, which is probably covered in the presence of the
intact SUMO consensusmotif. We noticed that under overexpression
conditions, only ~20% of ZIC3 WT is SUMO modiﬁed, and the
majority of the unmodiﬁed free ZIC3 WT still stays exclusively in
the nucleus. Also, we did not detect sumoylation of exogenous ZIC3
by the endogenous sumoylation machinery in the regular HeLa
cells (data not shown). Thus, we cannot conclude that SUMO conju-
gation is required for the exclusive nuclear localization of ZIC3 WT
unless the majority of WT ZIC3 is sumoylated, but is only partially
detectable due to the transient and dynamic nature of this modiﬁca-
tion in vivo. However, given the ﬁndings that PIAS1 WT—but not its
RING-mut—substantially restores the nuclear occupancy of K248R
mutant in the presence of SUMO-1, we argue that sumoylation is
involved inmediating the nuclear retention of ZIC3. The fact that signif-
icant augmentation of the nuclear accumulation of K248R after SUMO
conjugation is enhanced also suggests that even SUMO attachment to
non-canonical site(s) can contribute to ZIC3’s nucleocytoplasmic shut-
tling. Thus, SUMO conjugation plays a critical role in determining the
subcellular localization of ZIC3. However, we were unable to identifythe non-canonical SUMO site that is activated by K248R mutation,
which otherwise could be used to further test whether the existence
of PIAS1/SUMO-1 would be able to sequester a non-sumoylatable ZIC3
mutant within the nucleus.
A multitude of genes encoding SUMO targets are disease related.
Presumably, the mutations that occurred within the SUMO targeting
sequence negatively affected their sumoylation, thereby contributing
to disease development, as evidenced by the mutations in lamin A and
in the microphthalmia-associated transcription factor (MITF) [46,47].
However, the mutation of sites that are not in the SUMO attachment
sequence could also indirectly affect sumoylation and was potentially
involved in pathogenesis, such as those mutations of Tbx22 and Nkx2.5
[48,49]. In the present study, we provide another example of these
indirect effects. In the six human ZIC3 mutants examined, all three ZF1
mutants (C253S,W255G,H286R) and one ZF2mutant (T323M) suppress
sumoylation, while two other mutations (K405E, a mutation located in
the ZF5, and P217A, a mutation of the N-terminal domain of ZIC3) do
not. Interestingly, while sumoylation-normal mutants P217A and
K405E do not display signiﬁcant changes in the subcellular distribution
pattern compared with WT ZIC3, all sumoylation-deﬁcient mutants
tested (C253S, W255G, H286R and T323M) exhibit impaired nuclear
occupancy. More importantly, the abnormal cytoplasmic diffusion of
these mutants is reversed by restored sumoylation that is achieved by
co-expression of WT PIAS1/SUMO-1. It is noteworthy that the muta-
tions on ZF1 such as C253S, W255G and H286R are not part of any NLS
deﬁned previously [12,13].
Sumoylation-deﬁcient mutant K248R shows altered nuclear export,
which in turn, is blocked by LMB. To assess whether there is any similar
2732 L. Chen et al. / Biochimica et Biophysica Acta 1833 (2013) 2725–2733molecular phenotype underlyingK248Rand these sumoylation-defective
human ZIC3 variants, we selected three mutants C253S, W255G and
H286R for further examination. Indeed, LMB impedes the cytoplasmic
relocalization of all three of these mutants. Thus, these observations to-
gether argue that sumoylation might serve as a unifying mechanism
that dictates the nuclear occupancy of ZIC3. Given the diverse phenotypic
manifestations associated with alternative ZIC3 mutants, it is likely that
the degree of altered sumoylation activity of these ZIC3mutants contrib-
utes to the variable expressivity of phenotypes caused by these mutants.
In Xenopus embryo, the C253S, W255G and H286R mutants were
reported to be primarily located in the nucleus [14]. Given the observa-
tion that increased SUMO conjugation promotes the nuclear retention
of sumoylation-deﬁcient ZIC3 mutants, it would be interesting to see if
high SUMO conjugation activity exists in Xenopus embryo compared
with that of cell lines such as HeLa and NIH 3T3. We also noted that
LMB showed no signiﬁcant effects on the cytoplasmic localization of
some mutants (i.e., W255G and H286R) [12,13]. It is currently not clear
what accounts for the difference between our observation and theirs.
However, we realize that under our experimental conditions, the cyto-
plasmic diffusion of those mutants is not as “extreme” as observed in
those reports. Numerous experimental conditions could contribute to
the differences in experimental outcomes mentioned above.
5. Conclusion
We have demonstrated that zinc ﬁnger transcription factor ZIC3 is
modiﬁed by SUMO conjugation on the primary SUMO site lysine 248
and that lysine 248 is involved in regulating ZIC3's subcellular localiza-
tion. Mutations in human ZIC3 in ZF1 and 2 cause a decrease in SUMO
conjugation and abnormal subcellular distribution; and enhanced
sumoylation of these mutants in the presence of SUMO E3 ligase and
SUMO-1 reestablishes their nuclear accumulation. These ﬁndings col-
lectively support the notion that deﬁcient sumoylation of human ZIC3
variants underpins the aberrant extranuclear localization and provides
a potential strategy to salvage their normal subcellular distribution
by restoring SUMO conjugation. Whether other ZIC family proteins
are SUMO targets need further exploration. However, given the
evolutionally conserved SUMO consensus motif among paralogs and
orthologs of ZIC3, the sumoylation pathway must represent a common
pathway that governs the function of ZIC proteins.
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